Skin Cancer News and Research

Latest Skin Cancer News and Research

Therapy Finder - Colorectal Cancer app now available for patients

No one wants to hear the words, "you have colon cancer." For patients diagnosed with an advanced form of the disease, these words can be particularly devastating. The five-year survival rate can be a little as 6 percent. The top-of-mind question becomes, "Which treatment or clinical trial will work for me?"

28 Mar 2012

Cardiff team receives European grants to develop 'RealTCut' surgical simulation

Highly realistic surgical simulation which reduces patient risk has become the 100th Cardiff University project to win an award under the European Union's prime research funding scheme, the Seventh Framework Programme.

23 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

APN forms GPO partnership with ASDS

Aesyntix Physician Network (APN), a group purchasing organization (GPO) for dermatology and cosmetic surgery practices, and the American Society for Dermatologic Surgery (ASDS) today announced they have formed a partnership to provide ASDS members with significant savings opportunities on commonly purchased medical/surgical supplies and other products and services, including Revenue Cycle Management solutions.

17 Mar 2012

Abbott initiates enrollment in two HUMIRA Phase 3 trials for moderate to severe HS

Abbott today announced the initiation of two Phase 3 clinical trials designed to evaluate the safety and efficacy of an investigational use of HUMIRA (adalimumab) in adult patients with moderate to severe hidradenitis suppurativa.

16 Mar 2012

New topical gel decreases amount of time needed to treat actinic keratosis

A new topical gel now available by prescription significantly decreases the amount of time needed to treat actinic keratosis, a skin condition that is a common precursor to skin cancer, according to a multi-center trial led by researchers at Mount Sinai School of Medicine.

15 Mar 2012

PhotoMedex fourth quarter revenues increase 26% to $28.8M

PhotoMedex, Inc. today reported financial results for the three and 12 months ended December 31, 2011.

9 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

IDS, AADA disappointed in postponement of vote by Idaho on indoor tanning bed legislation

The Idaho Dermatology Society (IDS) and the American Academy of Dermatology Association (AADA) are disappointed in the postponement of the vote by the Idaho House of Representatives on House Bill 486, which would ban the use of indoor tanning beds by minors under the age of 18.

5 Mar 2012

Vitamin A daily dose may help prevent skin cancer: Study

A study has shown that a daily vitamin pill could help prevent skin cancer - particularly among women. Scientists say taking food supplements containing vitamin A can make people less likely to develop melanoma, the deadliest form of the disease.

4 Mar 2012

Metastatic melanoma patients with specific genetic mutation benefit from vemurafenib

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib - increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months.

1 Mar 2012

Non-invasive hyperspectral imaging system for skin cancer screening relies on Andor technology

Malignant melanoma (MM), the most dangerous type of skin cancer, is caused mainly by intense episodes of UV exposure and originates in the pigment-producing melanocytes in the basal layer of the epidermis. Early detection and complete excision of the primary lesions is crucial for reducing melanoma-related deaths but current diagnostic practice is highly subjective. This leads to unnecessary surgical procedures, which are highly-invasive and expensive.

1 Mar 2012

Collaborative study of physical activity patterns, eating habits in colorectal cancer patients

The five hospitals of Meridian Health, a System Partner of The Cancer Institute of New Jersey (CINJ), have joined forces with CINJ in offering a clinical research study that examines physical activity patterns and eating habits in colorectal cancer patients who have recently finished treatment.

27 Feb 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

Insight into relationship between two types of suppressors in cancerous tumors

The University of Kentucky has announced that Dr. Daret St. Clair, the James Graham Brown Endowed Chair and professor of toxicology, has published the first comprehensive study that provides insight into the relationship between two types of suppressors in cancerous tumors. The results will enhance the understanding of transcriptional mechanisms in carcinogenesis.

23 Feb 2012

Birmingham dermatologist first to offer anti-cellulite Cellulaze procedure

Dr. Barry Ginsburg, a Birmingham, AL based Dermatologist today announced his practice is the first in the state to offer the Cellulaze by Cynosure, the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market.

20 Feb 2012

EC approves Plexxikon's Zelboraf to treat BRAF mutation-positive MM

Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.

20 Feb 2012

UK's leading model agencies back 'No Sunbed' campaign

Ahead of London Fashion Week, leading model agencies sign groundbreaking 'No Sunbed' policy agreement as part of Cancer Research UK's R UV UGLY? campaign after warnings on health and appearance

17 Feb 2012

Combination of photodynamic therapy and software can treat internal tumours

Laser light in combination with certain drugs - known as photodynamic therapy - can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem.

16 Feb 2012